Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417126 · ClinicalTrials.gov registry record · Phase 2
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
A Phase 2 study, sponsored by Nanoscope Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05417126 is a Phase 2 study that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05417126, a Phase 2 study, has completed, sponsored by Nanoscope Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
Interventions
- BIOLOGICAL Gene Therapy-vMCO-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05417126
The ClinicalTrials.gov registry entry for NCT05417126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gene Therapy-vMCO-010 is the first listed.
NCT05417126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05417126 about?
NCT05417126 is a clinical study titled "Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease". The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
What is the current status of trial NCT05417126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-07-05. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05417126?
The interventions under investigation include: Gene Therapy-vMCO-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05417126?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.